The European Partnership for Personalised Medicine (EP PerMed) has announced a new call for proposals under the Horizon Europe programme. This initiative aims to foster groundbreaking research and development in personalised medicine, driving advancements that can lead to more tailored and effective healthcare solutions across Europe. The call seeks to fund collaborative projects that address key challenges in the field.
Key Takeaways
- Focus on collaborative research in personalised medicine.
- Funding available through the Horizon Europe programme.
- Aims to advance tailored healthcare solutions.
Advancing Personalised Medicine in Europe
The EP PerMed initiative is a significant step towards enhancing the European research area in personalised medicine. By pooling resources and expertise, the partnership aims to accelerate the translation of research findings into clinical practice, ultimately benefiting patients with more precise and effective treatments. This call specifically targets projects that demonstrate a clear potential for impact on public health and the European economy.
Horizon Europe Programme Funding
The Horizon Europe programme, the EU’s key funding instrument for research and innovation, provides the financial backing for this call. It supports projects that are expected to deliver significant scientific, technological, and societal advancements. The EP PerMed call is designed to align with the broader objectives of Horizon Europe, promoting European competitiveness and addressing global challenges.
Eligibility and Scope
While specific details regarding eligibility criteria and the exact scope of research areas will be outlined in the official call documentation, it is understood that proposals will need to demonstrate strong collaboration between academic institutions, research organizations, and industry partners. The focus is on projects that can tackle complex health issues through a personalised approach, potentially involving areas such as genomics, data analytics, diagnostics, and targeted therapies. Successful applicants will contribute to building a robust ecosystem for personalised medicine in Europe.
